# Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

> **NCT00064246** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 28 (actual)

## Conditions studied

- Post-transplant Lymphoproliferative Disorder
- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Stage III Adult Burkitt Lymphoma
- Stage III Adult Diffuse Large Cell Lymphoma
- Stage IV Adult Burkitt Lymphoma
- Stage IV Adult Diffuse Large Cell Lymphoma
- Waldenström Macroglobulinemia

## Interventions

- **BIOLOGICAL:** rituximab
- **RADIATION:** indium In 111 ibritumomab tiuxetan
- **RADIATION:** yttrium Y 90 ibritumomab tiuxetan

## Key facts

- **NCT ID:** NCT00064246
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2004-09
- **Final completion:** —
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2013-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00064246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00064246, "Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00064246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*